Epiprobe anamaliza pafupifupi RMB 100 miliyoni ya Series B ndalama

Posachedwapa, Shanghai Epiprobe Biotechnology Co., Ltd. (amatchula "Epiprobe") analengeza kuti anamaliza pafupifupi RMB 100 miliyoni mu Series B ndalama, amene pamodzi padera ndi likulu mafakitale, nsanja ndalama boma ndi kutchulidwa kampani Yiyi Shares (SZ). :001206).

Yakhazikitsidwa mu 2018, Epiprobe, monga wothandizira komanso mpainiya wowunika koyambirira kwa khansa ya pan-cancer, ndi bizinesi yapamwamba kwambiri yomwe imayang'ana kwambiri za matenda a khansa ndi mankhwala olondola.Kumanga gulu lapamwamba la akatswiri a epigenetics komanso kudzikundikira kwakukulu kwamaphunziro, Epiprobe amawunika momwe angadziwire khansa, amathandizira masomphenya a "kuteteza aliyense kutali ndi khansa," odzipereka kuti azindikire msanga, kuzindikira msanga komanso kuchiza khansa, potero kuwongolera kupulumuka. kuchuluka kwa odwala khansa kuti apititse patsogolo thanzi la anthu onse.

Atatha kukumba kwa zaka 20, gulu lalikulu la Epiprobe lidapeza pawokha mitundu ingapo ya khansa ya Aligned General Methylated Epiprobes (TAGMe), yomwe imapezeka paliponse m'makhansa osiyanasiyana, motero ikukulitsa gawo lofunsira.

Ponena za ukadaulo wozindikira, pyrosequencing mwamwambo imatengedwa ngati "golide muyezo" pozindikira methylation, yomwe imadalira kutembenuka kwa bisulfite, koma imakhala ndi zophophonya monga kusasunthika kosakhazikika, kuwonongeka kosavuta kwa DNA, zofunika kwambiri kwa ogwiritsa ntchito, komanso kudalira zida zamtengo wapatali.Kuperewera kumeneku kumachepetsa kugwiritsidwa ntchito kwake.Epiprobe, popanga luso laukadaulo, pawokha apanga ukadaulo wodziwikiratu wa methylation - Me-qPCR popanda chithandizo cha bisulfite, chomwe chimachepetsa mtengo ndikuwongolera kukhazikika kwa kuzindikira komanso kugwira ntchito kwachipatala, kupangitsa kuzindikira kukhala kosavuta komanso kosavuta.

Epiprobe, yomwe imayang'ana kwambiri zolembera za khansa ya pan-cancer ndi njira zodziwira matenda a methylation, yagwiritsa ntchito ma patent opitilira 50 apakhomo ndi apadziko lonse lapansi, ndipo yalandila chilolezo chokhazikitsa patent yokhazikika.

Pakadali pano, Epiprobe yagwira ntchito limodzi ndi zipatala zopitilira 40 ku China, kuphatikiza Chipatala cha Zhongshan, Chipatala cha International Peace Maternity and Child Health Hospital, ndi Chipatala cha Changhai ndi zina zambiri, ndipo yakhazikitsa njira zambiri zamatenda a khansa yaubereki (kuphatikiza khansa ya khomo lachiberekero, khansa ya endometrial) , khansa ya mkodzo (kuphatikizapo khansa ya chikhodzodzo, khansa ya mkodzo, khansa ya m'chiuno), khansa ya m'mapapo, khansa ya chithokomiro, khansa ya m'magazi ndi khansa zina.Kutsimikizika kwakhungu kawiri kwachitika mu zitsanzo zachipatala 70,000 zomwe zili ndi mitundu 25 ya khansa.

Zina mwazogulitsa, zodziwikiratu za khansa ya ubereki wa amayi, kutsimikizika kwakhungu kawiri kwakhazikitsidwa mu zitsanzo zachipatala zopitilira 40,000, ndipo zotsatira za kafukufuku zasindikizidwa m'magazini odziwika padziko lonse lapansi monga Cancer Research, Clinical and Translational Medicine, ndi mayesero azachipatala akuluakulu apakati ambiri akugwiridwa.Pamene R&D ikupita patsogolo komanso chuma chikuchulukirachulukira, mapaipi amakampani akuchulukirachulukira.

Mayi Hua Lin, CEO wa Epiprobe ananena kuti: “Ndi mwayi wathu waukulu kuzindikiridwa ndi kuthandizidwa ndi mizinda yabwino kwambiri ya mafakitale.Epiprobe imadziwika ndi kudzikundikira kwake kwamaphunziro, ukadaulo wapadera, komanso kafukufuku wokhazikika wachipatala, zomwe zapangitsa kuti magulu ambiri azikhulupirira.Pazaka zinayi zapitazi, gulu la kampani ndi ntchito zake zakhala zikuyenda bwino.M'masiku akubwerawa, sitidzayesetsa kuitanira anzathu omwe ali ndi malingaliro ofanana kuti agwirizane ndikugwira ntchito limodzi, potero kulimbikitsa nthawi zonse R&D ndi njira yolembetsa yolembetsa, komanso kupatsa azachipatala ndi odwala chithandizo chabwino kwambiri choyezera khansa komanso mankhwala.”